Blogs
Core Lithium (ASX: CXO): Finniss Restart and Tactical Re‑rating
Core Lithium (ASX: CXO) advances its Finniss restart with full funding, disciplined execution, and improving lithium sentiment, positioning for a tactical rebound as operations resume and technical momentum builds.
.webp&w=828&q=75)
Cobre (ASX: CBE)’s Copper Pivot: Cash flow, Chile Expansion & Chart nerves
Cobre is shifting from exploration to production, backed by positive cash flow at Sierra Atacama and ongoing Botswana exploration. While the share price remains strong, investors are watching whether the company can sustain operational momentum and long-term growth.
Computershare (ASX: CPU): Consistent Growth and Margin Resilience
Computershare (ASX: CPU) delivers consistent earnings growth and margin resilience through disciplined cost control, strong cash generation, and capital‑light operations, positioning for sustained shareholder returns.
Suncorp Group (ASX: SUN): Re‑Establishing Margin Strength Through Digital Scale and Capital Discipline
Suncorp Group (ASX: SUN) delivers resilient margins despite elevated natural hazards, supported by AI‑driven transformation, disciplined capital management, and strong portfolio optimisation.
Solstice Minerals (ASX: SLS) Breaks Out as Nanadie Turns into a Bigger Copper- Gold Story
Solstice Minerals has gained momentum after strong drilling results at its Nanadie copper-gold project. The explorer is expanding its resource potential, backed by fresh funding, multiple exploration targets, and a bullish share price breakout supported by rising trading volume.
Weebit Nano (ASX: WBT) Breaks Gear as ReRAM Moves from Promise to Production
Weebit Nano is gaining investor attention as commercial progress accelerates. Licensing deals, JEDEC qualification, product tape-outs, stronger revenue, and fresh funding have boosted confidence. At the same time, the share price remains technically strong with buyers defending key support levels after a significant breakout.
Fundamental Analysis: What It Is, Its Main Types, and How to Use It
Fundamental analysis calculates a security's intrinsic value by evaluating macroeconomic, industry, and company-specific financial data. Unlike technical analysis, this long-term strategy identifies mispriced assets based on underlying business health, though it demands significant research, reliable data, and patience
Challenger (ASX: CGF): The Business Case Behind the Recent Shift in Sentiment
Challenger (ASX: CGF) delivers disciplined growth and capital strength, positioning itself as Australia’s leading retirement‑income compounder with expanding annuity sales, resilient margins and a robust balance sheet.
Manuka Resources (ASX: MKR) Pulls Back as the Restart Rally Meets Its First Real Test
Manuka Resources is retracing after its May rally as investors await production milestones. With gold processing expected in July and silver production targeted for September, the market is looking for operational results to confirm the company's restart strategy.
Inoviq (ASX: IIQ)'s Breakout Reverses Hard: IIQ Slides After EXO-OC Study Reset
Inoviq shares plunged after sample-quality issues delayed validation of its EXO-OC ovarian cancer test, despite improved algorithm performance. The sharp reversal has shifted investor focus from growth potential to execution risks, timelines, and confidence in the company’s development strategy.
Macquarie Group (ASX: MQG): A High‑Conviction Financial Powerhouse
Macquarie Group (ASX: MQG) delivers muscular earnings growth, disciplined capital management and diversified global momentum, positioning itself as Australia’s premier financial powerhouse with sustainable mid‑teen returns and expanding shareholder value.
QBE Insurance Group (ASX: QBE): High-Conviction Income and Compounding Returns
QBE Insurance Group (ASX: QBE) delivers disciplined underwriting, robust investment returns and rising capital returns, offering high-conviction, income-led exposure to global commercial insurance with upside from sustained double-digit ROE and capital-efficient growth.
What Is a Trending Market? A Complete Guide to Identifying Trending Markets and Growing Profits
Successful trading depends on aligning with market conditions, especially trends. This article explains how to distinguish trending from range-bound markets, identify uptrends and downtrends, use key technical tools for entries and exits, and avoid common mistakes that lead to losses.
Judo Capital Holding (ASX: JDO) Credit Shock: Falls Hard, but the Chart Is Now Screaming “Decision Point”
Judo Capital (ASX: JDO) has dropped sharply after a credit-quality shock, lifting cost-of-risk guidance and cutting profit forecasts. Heavy selling, oversold technicals, and weak sentiment now define the stock, though long-term growth signals remain partly intact.
Ansell (ASX: ANN): Margin Expansion and Operational Resilience Through Transition
Ansell (ASX: ANN) delivers double‑digit earnings growth, disciplined cost control, and strong cash conversion amid subdued market conditions, reinforcing margin resilience and balance‑sheet strength.
Mesoblast (ASX: MSB) Shares Declined Despite Ryoncil Momentum as Investors Lock In Profits
Mesoblast (ASX: MSB) is transitioning into a commercial-stage biotech as Ryoncil® sales accelerate and its late-stage pipeline advances. While the share price has eased after a strong rally, growing revenue, improving cash flow, and multiple clinical catalysts continue to support its long-term outlook.
Artrya (ASX: AYA) Pulls Back After Testing Fresh 52-Week Highs
Artrya (ASX: AYA) is consolidating after a strong rally as investors assess its U.S. expansion, FDA progress, and commercial rollout of the AI-powered Salix platform. Despite the pullback, growing adoption and clinical milestones continue to support its long-term growth outlook.
Cyprium Metals (ASX: CYM): Re‑Emerging as Australia’s Next Copper Producer
Cyprium Metals (ASX: CYM) advances toward first copper cathode production at Nifty, backed by strong funding, disciplined execution, and a clear growth pipeline across Western Australia.
Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.
4DMedical (ASX: 4DX) Pulls Back After Breakout Rally
4DMedical slipped to A$4.57 after its breakout rally, as traders took profit near A$5.00. Momentum remains constructive, but holding A$4.25–A$4.50 is crucial while CT expansion, acquisitions and SaaS growth support the broader story.
Woodside Energy Group (ASX: WDS): Repricing Resilience and Capital Discipline
Woodside Energy (ASX: WDS) delivers strong cash generation, disciplined capital allocation, and resilient margins amid volatile LNG markets, positioning for long‑term value through diversified energy growth.